Following the successful launch of generic Glimepiride in a number of European markets, Actavis Limited launched its product in Malta.
Glimepiride is indicated for the treatment of diabetes, where the increased blood
glucose cannot be adequately controlled by diet, physical exercise and weight
reduction. In a press release, the company explained that it has launched Glimepiride
into a number of EU markets last December to coincide with the expiry of the originator's